Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
- Resource Type
- Article
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia November 2021 21(11):e886-e894 - Subject
- Language
- ISSN
- 2152-2650